Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Postmarket Surveillance Reform Board Gets Injection Of Device Industry Experience

This article was originally published in The Gray Sheet

Executive Summary

The appointments of three device industry veterans to the Brookings-administered, and partially FDA-funded, Planning Board is intended to expand the range of input in the next phase of development of a new National Medical Device Surveillance System.

You may also be interested in...



Negotiating Prices For Real-World Data Can Lower FDA Submission Costs, Shuren Says

A new national evaluation system for devices will provide collective bargaining power to reduce the costs of real-world data to substitute for clinical trials in company submissions.

Device Surveillance Reform Board Looks To Add Small-Firm Experience

The public-private National Medical Device Evaluation System Planning Board, first convened in 2014, is seeking nominations for new members to support the next two-year phase of development of a revamped postmarket surveillance system.

Task Force Advocates Making Registries Better Than Sum Of Their Parts

The FDA-endorsed Medical Device Registry Task Force maps out a path toward "coordinated registry networks," starting with pilot projects and 11 prioritized device categories.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel